Protection of nascent competition at centre of FTC order on medical technology deal

The Federal Trade Commission is requiring medical device company Medtronic to divest a subsidiary of Intersect ENT that is alleged to be a nascent competitor to proceed with its $1.1 billion purchase of the medical technology company.

Get unlimited access to all Global Competition Review content